Conference
Why Has the Use of Health Economic Evaluation in Japan Lagged Behind that in Other Developed Countries?
Abstract
The aging population and the increasing availability of new medical technologies, particularly pharmaceuticals, have led to growing pressure on governments worldwide to contain healthcare costs. Increasingly, economic evaluation is used to aid decisions on the reimbursement and formulary access of drugs, and pharmaceutical companies are often required to demonstrate the cost effectiveness of their products. Canada and the UK are examples of …
Authors
Ikegami N; Drummond M; Fukuhara S; Nishimura S; Torrance GW; Schubert F
Volume
20
Pagination
pp. 1-7
Publisher
Springer Nature
Publication Date
11 2002
DOI
10.2165/00019053-200220002-00001
Conference proceedings
PharmacoEconomics
Issue
Suppl 2
ISSN
1170-7690